Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umeclidinium Bromide Dose Finding in Asthma
NCT03012061Phase 2Completed
- Sponsor
- GSK
- Start
- Jan 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of umeclidinium in asthma (3 arms), sponsored by GSK. Primary endpoint: Mean Change From Baseline in Clinic Trough Forced Expiratory Volume in 1 Second (FEV1) at 24 weeks. Started Jan 2017; status: completed.
02
Drugs
umeclidinium
03
Conditions
asthma
Beyond the preview
Go deeper on NCT03012061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012061.